Literature DB >> 15509617

Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis.

Jill P Adler-Moore1, Jon A Olson, Richard T Proffitt.   

Abstract

OBJECTIVES: This study was done to determine whether high dose AmBisome (4-20 mg/kg), given intermittently, could reduce the frequency of dosing needed to treat murine systemic candidiasis when compared with conventional daily treatment.
METHODS: Mice were immunosuppressed with cyclophosphamide every 3 days, beginning day -3 before challenge with log(10) 5.0 cfu Candida albicans. Treatment was begun 48-72 h post-challenge with daily or intermittent dose regimens of AmBisome, followed by determination of kidney cfu for up to 1 month post-treatment.
RESULTS: A single AmBisome dose of 4 mg/kg was as effective as four daily, 1 mg/kg treatments. A total of 8 mg/kg, given as 4 mg/kg on days 2 and 4, or as 5 mg/kg on day 2 followed by 1 mg/kg on days 3, 4, and 5, also produced comparable efficacy. While 20 mg/kg given day 2, 4 and 6 post-challenge as a 1 week loading dose, followed by one 10 mg/kg treatment on day 13, decreased the fungal burden by up to 5 logs compared with controls (log(10) 2.3 cfu/g and log(10) 7.5 cfu/g, respectively), 20 mg/kg given Monday, Wednesday and Friday for 5 weeks, reduced the fungal burden to undetectable levels (i.e. log(10) 1.0 cfu).
CONCLUSIONS: Significant reduction or clearance of kidney cfu, following intermittent, high dose AmBisome treatment, indicated that non-daily dosing regimens could be successfully used instead of conventional daily dosing to treat established C. albicans infection in immunosuppressed mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15509617     DOI: 10.1093/jac/dkh460

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.

Authors:  D Andes; N Safdar; K Marchillo; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis.

Authors:  Russell E Lewis; Nathaniel D Albert; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2008-08-25       Impact factor: 5.191

3.  Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.

Authors:  Jon A Olson; Jill P Adler-Moore; P J Smith; Richard T Proffitt
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 4.  Extended Dosing Regimens for Fungal Prophylaxis.

Authors:  Thomas Lehrnbecher; Konrad Bochennek; Thomas Klingebiel; Silke Gastine; Georg Hempel; Andreas H Groll
Journal:  Clin Microbiol Rev       Date:  2019-05-15       Impact factor: 26.132

5.  Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.

Authors:  Luciana Annino; Anna Chierichini; Barbara Anaclerico; Erica Finolezzi; Marianna Norata; Stefania Cortese; Maria Iris Cassetta; Stefania Fallani; Andrea Novelli; Corrado Girmenia
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

6.  Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem cell transplant patients.

Authors:  Paul O Gubbins; Jarrett R Amsden; Scott A McConnell; Elias J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

7.  Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens.

Authors:  William W Hope; Joanne Goodwin; Timothy W Felton; Michael Ellis; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

Review 8.  Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice.

Authors:  Athanasios Tragiannidis; Charalampos Dokos; Thomas Lehrnbecher; Andreas H Groll
Journal:  Drugs       Date:  2012-03-26       Impact factor: 11.431

9.  Effect of Delta-9-tetrahydrocannabinol on mouse resistance to systemic Candida albicans infection.

Authors:  Gideon W Blumstein; Arya Parsa; Anthony K Park; Beverly L P McDowell; Melissa Arroyo-Mendoza; Marie Girguis; Jill P Adler-Moore; Jon Olson; Nancy E Buckley
Journal:  PLoS One       Date:  2014-07-24       Impact factor: 3.240

10.  Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B.

Authors:  Robert J van de Peppel; Alexander Schauwvlieghe; Ruth Van Daele; Isabel Spriet; Jan W Van't Wout; Roger J Brüggemann; Bart J A Rijnders; Bart J C Hendriks; Mark G J de Boer
Journal:  Med Mycol       Date:  2020-10-01       Impact factor: 4.076

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.